The influence of cyclic AMP on cartilage degradation was investigated by using phosphodiesterase inhibitors [theophylline and 3-isobutyl-l-methylxanthine (IBMX)], forskolin (which activates the catalytic subunit of adenylate cyclase) and cyclic AMP analogues (dibutyryl and 8-bromo). Breakdown was assessed by quantification of proteoglycans released into the media of 8-day bovine nasal-septum cartilage cultures. Theophylline (1-20 mM), IBMX (0.01-2 mM) and dibutyryl cyclic AMP (0. 1-2 mM) had little or no influence on the rate of proteoglycan release from unstimulated (no-endotoxin) cartilages. A small but detectable increase in breakdown was observed with 8-bromo cyclic AMP (0.5-2 mM) and forskolin (50-75 ,ug/ml). To examine potential inhibitory influences of these agents, the cyclic AMP modulators were added to cultures simultaneously treated with Salmonella typhosa endotoxin (12-25 ,ug/ml), a potent stimulator of cartilage degradation. The 3-4-fold stimulation of breakdown by endotoxin was strikingly inhibited by all three classes of cyclic AMP regulators. Optimal inhibition was found at 10-20 mM-theophylline, 1-2 mM-IBMX, 50-75 #sg of forskolin/ml, 2 mM-dibutyryl cyclic AMP and 2 mM-8-bromo cyclic AMP.
INTRODUCTION
Cyclic AMP is an important intracellular second messenger and regulator in many biological systems. Several studies suggest that it is important in chondrocyte metabolism. For example, cyclic AMP analogues have been shown to stimulate chondrocyte DNA synthesis [1] , RNA synthesis [2] , amino acid transport [3, 4] and macromolecular synthesis [5] [6] [7] . In addition, similar effects have been shown by using agents (such as theophylline and IBMX) which modulate endogenous cyclic AMP concentrations [1, [3] [4] [5] .
Unlike anabolic processes, little is known about the influence of cyclic AMP on cartilage catabolism. Dibutyryl cyclic AMP and 8-bromo cyclic AMP were shown to inhibit the release of matrix proteoglycans synthesized by isolated rat costal cartilage chondrocytes [8] . On the other hand, dibutyryl cyclic AMP stimulated the release of proteoglycans from immature rabbit ear cartilage [9] .
We [10] [11] [12] [13] [14] and others [15] [16] [17] [18] have been studying cartilage degradation using bovine nasal-cartilage discs cultured in the presence of stimulators such as bacterial endotoxin (lipopolysaccharides), rheumatoid synovial membranes or synovium-conditioned media, and interleukin-1 (IL-1; which appears to be similar to or identical with catabolin). Endotoxin, a readily available stimulator, provides an especially useful probe with which to study the biochemical mechanism of cartilage degradation, because of its striking potency in vitro.
In this study, we examined the effects of cyclic AMP modifiers on degradation in unstimulated and endotoxinstimulated cartilage. Results and N6,2'-O-dibutyryl cyclic AMP were also purchased from Sigma. The dibutyryl cyclic AMP was reported to contain 1-3o% of a monobutyryl derivative.
Cartilage degradation assay
Cartilage degradation was assayed by measurement of proteoglycan released during eight days of culture, by a modification of the procedures previously described [10, 16, 17] [10, 12] . Proteoglycan assay Proteoglycan was assayed by using the metachromatic dye 1,9-dimethylMethylene Blue [19] . A stock solution (16 mg of dye dissolved in 5 ml of ethanol + 95 ml of 0.1 M-formate buffer, pH 3.5) was diluted 1:10 with 0.1 M-formate buffer before use. Dye (5 ml) was added to 10- [20] analysis was used to determine statistically significant differences between control and experimental groups.
Characterization of 135Sisulphate-labelied products Radioactively labelled proteoglycan products released from prelabelled cartilage were characterized as previously described [10, 13] . Briefly, cartilage discs incubated for 24-48 h in complete DMEM (MgCl2 substituted for MgSO4) containing 10-20 ,Ci of Na235SO4/ml (2 ml/disc) were washed three times in Hanks' solution and re-incubated for 24 h in non-radioactive (MgSO4-replete) medium. Using this labelling procedure we have previously shown that nearly all of the incorporated [35S]sulphate is in high-Mr proteoglycan complexes, and > 90% was identified as proteoglycan chondroitin sulphate [10, 14] . Radioactive discs were then incubated as described above in the 8-day cartilage-degradation assay. Labelled products released into the culture media and residual labelled proteoglycan in the cartilage discs were analysed by gel-filtration chromatography. Cartilage proteoglycan was extracted directly into column elution buffer (see below) by vigorous shaking at 4°C, with two changes of 2.5 ml each per disc. Medium (0.5 ml) from control or experimental groups was mixed with an equal volume of elution buffer and applied to a 1.5 cm x 29 cm Sepharose CL-2B column. Cartilage extracts were applied directly. Column elution was at 12 ml/h with a dissociative buffer composed of 4 M-guanidinium chloride, 0.15 M-sodium acetate buffer (pH 7.0) and proteinase inhibitors (phenylmethanesulphonyl fluoride, benzamidine hydrochloride and iodoacetamide, all 1 mM). Fractions (1 ml) were collected and counted for radioactivity in a Packard 3320 liquidscintillation counter. Calibration markers (and their peak elution positions) included Na235SO4 (S, fraction no. 45) and Blue Dextran 2000 (VO, fraction no. 15). The Mr distribution of products was based on their elution volume (Ve).
RESULTS
Effects ofthe phosphodiesterase inhibitors theophylline (1-20 mM) and IBMX (0.01-2 mM) on unstimulated and endotoxin-enhanced cartilage degradation are shown in Fig. 1 . Neither agent, at any of the concentrations used, caused a significant change in basal release of cartilage proteoglycan. In contrast, endotoxin-stimulated breakdown (approx. 2-fold) was inhibited in a dose-dependent fashion, detectable at about 5 mM-theophylline and 0.01 mM-IBMX. At maximal inhibitory doses (10-20 mmtheophylline and 1-2 mM-IBMX), breakdown was decreased nearly to control values.
Like the phosphodiesterase inhibitors, forskolin (5-75,ug/ml) greatly decreased endotoxin-stimulated catabolism in a dose-dependent manner (Fig. 2) . Detectable inhibition was found at 5 ,tg/ml, with optimal effect at approx. 75 ,ug/ml. Samples treated with forskolin alone showed a minor increase in basal proteoglycan release.
As a third independent mechanism to increase cartilage cyclic AMP, dibutyryl cyclic AMP and 8-bromo cyclic AMP were added to unstimulated and endotoxintreated cartilages (Fig. 3) . Both of these analogues depressed endotoxin-mediated breakdown in a concentration-dependent manner. Dibutyryl cyclic AMP (2 mM) decreased proteoglycan release from endotoxintreated samples by 75%, whereas 2 mM-8-bromo cyclic AMP depressed breakdown to control values. When added without endotoxin, 8-bromo cyclic AMP appeared to enhance breakdown to a small degree at 0.5-2 mm (Fig. 3b) , whereas dibutyryl cyclic AMP had no detectable effect (Fig. 3a) .
Inhibition by the cyclic-AMP-modulating agents was found to be reversible. Thus, although endotoxinmediated breakdown was largely inhibited during an initial 4-day culture period in the presence of theo- phylline, forskolin or dibutyryl cyclic AMP, degradation was completely restored when the agents were removed on day 4 and endotoxin alone was added. Indeed, the rates of proteoglycan depletion during days 4-8 in previously inhibited cultures were comparable with the initial rates (days 0-4) induced by endotoxin in the absence of each inhibitor. By day 8 of culture, proteoglycan depletion was extensive (approx. 90%) in cartilages treated with endotoxin alone for the last 4 days of culture. This was true after relief of inhibition, whether the initial (day 0-4) cultures were made in the presence or absence of endotoxin. Proteoglycan products released into the culture medium and those remaining in cartilage at the end of the experiment were analysed by gel-filtration chromatography (Fig. 4) . In unstimulated cultures, [35S]proteoglycans extracted from cartilage after an 8-day period were eluted as a single broad proteoglycanmonomer peak largely excluded from the gel (Fig. 4c) . This was comparable with the elution profile of monomers from uncultured cartilage. Products released into the culture medium showed a minor decrease in peak radioactivity, a slight shift to the right, as well as the (Fig. 4c ). Simultaneous treatment with either class of inhibitor restored the cartilage proteoglycan profiles toward control levels, with retention of a high-Mr exclusion peak, and limited contribution from smaller species (Figs. 4f and 4i ).
DISCUSSION
Endotoxin, a potent stimulator of proteoglycan release from cartilage in vitro, is a useful probe with which to study the biochemical events associated with cartilage degradation. Although the mechanism of its action is not clearly understood, it seems likely that endotoxin directly promotes chondrocyte degradative activity. Indeed, isolated bovine articular chondrocytes in confluent culture demonstrate a similar endotoxin response, with extensive breakdown of soluble proteoglycan monomers [22] and release of large amounts of proteoglycan-degrading neutral proteinase (J. J. Steinberg, unpublished work). On the other hand, the bovine nasal cartilage used in the present experiments, even though from the relatively avascular portion of the septum, may have small vascular channels which will contain endothelial and blood cells. Hence, the tissue may be a source of IL-1, a potent stimulator of cartilage degradation [21, [23] [24] [25] ; the possibility that endotoxin stimulates breakdown via endogenous IL-1 production cannot be entirely excluded. Moreover, the present findings that enhanced cyclic AMP concentrations inhibit breakdown could be consistent with that possibility, in view of the report that cyclic AMP inhibits IL-1 production in U937 leukaemic cells [26] .
However, for several reasons we consider that alterations in endogenous IL-1 production, if they do occur, are unlikely to account for the present findings. Firstly, articular cartilage shows a similar, but slower, .1987 degradative response to endotoxin ( [27] ; J. J. Steinberg, unpublished work). Such cartilage is not penetrated by blood vessels and therefore is unlikely to show significant IL-1 production, although an unconfirmed report suggests that chondrocytes may themselves be a source of IL-1 [28] . Secondly, endotoxin-simulated breakdown is largely unaffected by simultaneous treatment with anti-(human IL-1) serum (Genzyme, Boston, MA, U.S.A.) at concentrations that effectively block (by 60% or more) the cartilage-degradative response to IL-1 (M. Yodlowski, J. R. Hubbard & J. J. Steinberg, unpublished work). Although high-affinity membrane receptors for human IL-I have been demonstrated in bovine cells [29] , a difference in species-specific antibody responsiveness cannot be excluded. Thirdly, the degradation of proteoglycan monomers in response to endotoxin (Fig.  4) is far more extensive than that generally produced by IL-1 [21, 24, 25] . Lastly, differential responses to inhibitors further distinguish the two agents: cortisol inhibits endotoxin-stimulated breakdown in a dose-dependent manner [30] , but has little or no effect at concentrations as high as 10 tM on IL-i-induced breakdown [24] ; polymyxin B treatment has been shown to abolish the cartilage matrix-degrading activity of endotoxin, but not of blood mononuclear-cell factors containing IL-1 [15] .
In this investigation we have shown that five different modulators of cellular cyclic AMP, acting via three independent mechanisms [(i) blockade of cyclic AMP degradation through phosphodiesterase inhibition, (ii) activation of the catalytic subunit of adenylate cyclase through forskolin action, and (iii) directly elevating cyclic AMP concentrations by the use of membranepermeable cyclic AMP analogues] cause both quantitative and qualitative inhibition of endotoxin-mediated breakdown of bovine nasal cartilage in vitro. These observations strongly suggest that increasing intracellular cyclic AMP blocks the cartilage-destructive potential of endotoxin. Since little is known about the mechanism of endotoxin action on cartilage or about cartilage catabolism in general, the present findings may lead to a clearer understanding of how cyclic AMP is related to these processes. Whether cyclic AMP acts to prevent the production of a second regulator or directly blocks a catabolic cascade is yet to be determined. Studies on the specificity of this cyclic AMP response and its potential clinical value are also of future interest.
In previous studies, endotoxin has been shown to cause proteoglycan release from living, but not from dead, cartilage [15, 31] . Hence the restoration of a potent degradative response to endotoxin after relief from the inhibitory effects of cyclic AMP modulators indicates that these agents were not merely exhibiting a toxic effect on the tissue.
The results of this study are consistent with our observation that at high concentrations indomethacin blocks the destructive action of endotoxin on cartilage [32] . At similar concentrations, Newcombe et al. [33] showed that indomethacin acts as a potent inhibitor of articular-cartilage cyclic nucleotide phosphodiesterase.
Our findings are also consistent with those of Miller & Erickson-Lucas [8] , who found suppression of proteoglycan release by 8-bromo cyclic AMP and by dibutyryl cyclic AMP in a foetal-rat chondrocyte system. However, stimulation of breakdown by theophylline and dibutyryl cyclic AMP was noted by Shinmei et al. [9] , using immature rabbit ear cartilage. Such conflicting reports may reflect the differences in the experimental conditions or sources of cartilage. Studies are required to determine if the observations discussed in the present paper are similar for different types of cartilage and cartilage from different species.
Endotoxin-stimulated breakdown resulted in the release of most of the cartilage proteoglycan during an 8-day culture period. The released products, although much decreased in hydrodynamic size, were broadly distributed over a range of relatively high Mr values. We have previously shown [10] that this pattern is indicative of extensive core-protein proteolysis. The current findings suggest that enhancement of cyclic-AMPdependent mechanisms inhibits the generation of endotoxin-induced breakdown products by a decrease in core proteolysis.
